NCCN Guidance on Gene Profiling in Early-Stage HR+ Breast Cancer

May 21, 2021

Video

Debu Tripathy, MD, of the University of Texas MD Anderson Cancer Center, comments on current NCCN recommendations for the use of prognostic and predictive gene profiling assays to individualize treatment in patients with HR-positive breast cancer.

EP: 1.Optimizing Systemic Therapy for Early-Stage HR+ Breast Cancer

EP: 2.Perioperative Decision-Making in HR+ Breast Cancer

EP: 3.Role of Gene Profiling Assays in Early-Stage HR+ Breast Cancer

EP: 4.The Oncotype DX Breast Recurrence Score: Clinical Trial Data

EP: 5.Gene Profile-Directed Therapy for Early-Stage HR+ Breast Cancer

Now Viewing

EP: 6.NCCN Guidance on Gene Profiling in Early-Stage HR+ Breast Cancer

EP: 7.Informed Decision-Making in HR+ Breast Cancer

EP: 8.Neoadjuvant Therapy for HR+ Breast Cancer

EP: 9.Genomic Assays and Adjuvant Therapy for HR+ Breast Cancer

EP: 10.Genomic Testing vs Genetic Testing for HR+ Breast Cancer

EP: 11.The Oncotype DX Breast Recurrence Score for HR+ Breast Cancer

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!